Opiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) will report its financial results for Q2 2022 on August 11, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) will report its financial results for Q2 2022 on August 11, 2022, after market close. A conference call with management is scheduled for the same day at 4:30 p.m. ET, accessible via U.S. and international lines. Opiant, known for its NARCAN® Nasal Spray, focuses on developing treatments for addiction and drug overdose. For further details, visit www.opiant.com.
Positive
- Company scheduled to report financial results on August 11, 2022, which could highlight growth and operational performance.
Negative
- None.
Details
News Market Reaction – OPNT
The recorded move for OPNT in the trading session of this news was +3.77%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SANTA MONICA, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the second quarter ended June 30, 2022, after the financial markets close on Thursday, August 11, 2022.
The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Thursday, August 11, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13730815. To access the live webcast, please visit https://viavid.webcasts.com/starthere.jsp?ei=1556372&tp_key=6cb19180df. Following the live webcast, an archived version of the call will be available on the website.
Thursday August 11 @ 4:30 pm ET
| Domestic: | 1-877-407-0792 |
| International: | 1-201-689-8263 |
| Conference ID: | 13730815 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1556372&tp_key=6cb19180df |
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com.
For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.